adalimumab vs etanercept
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriatic Arthritis
Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07398651 (registry estimate)
No aligned efficacy figure on record for this race.
etanercept · Enbrel
Marketed by Amgen and partners
NCT00317499 · Phase 3 · completed
Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and week 24): ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) (met)
Result source: NCT02376790
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | etanercept |
|---|---|---|
| ACR20 | —Not posted · NCT00646178 | 60.9% vs 50.7%vs MethotrexateNCT0237679015 other results
|
| ACR50 | —Not posted · NCT00646178 | 63% vs 49.3%vs MethotrexateNCT0237679013 other results
|
| PASI 75 | —Not posted · NCT00646178 | —Not posted · NCT00317499 |
| Minimal disease activity | 41.5% vs 13.1%vs MTXNCT028141757 other results
| 51.3% vs 35.8%vs MethotrexateNCT0237679013 other results
|
| HAQ-DI, change | -0.5 vs -0.3vs MTXNCT02814175 | -0.5 vs -0.4vs MethotrexateNCT0237679015 other results
|
ACR20
- adalimumab
- —Not posted · NCT00646178
- etanercept
- 60.9% vs 50.7%vs MethotrexateNCT02376790
15 other results
- 65% vs 50.7% NCT02376790
- 83.1% vs 70.7% NCT02376790
- 80.4% vs 70.7% NCT02376790
- 77% vs 66.3% NCT02376790
- 74.2% vs 66.3% NCT02376790
- 67.6% vs 56.9% NCT02376790
- 71.9% vs 56.9% NCT02376790
- 69.5% vs 58.5% NCT02376790
- 71.8% vs 58.5% NCT02376790
- 65.5% vs 46.8% NCT02376790
- 70.3% vs 46.8% NCT02376790
- 60.2% vs 46.5% NCT02376790
- 60.8% vs 46.5% NCT02376790
- 44.3% vs 25% NCT02376790
- 46.4% vs 25% NCT02376790
ACR50
- adalimumab
- —Not posted · NCT00646178
- etanercept
- 63% vs 49.3%vs MethotrexateNCT02376790
13 other results
- 60.2% vs 49.3% NCT02376790
- 57.3% vs 41.8% NCT02376790
- 56% vs 41.8% NCT02376790
- 44.4% vs 30.6% NCT02376790
- 45.7% vs 30.6% NCT02376790
- 43.8% vs 29.2% NCT02376790
- 43.4% vs 29.2% NCT02376790
- 40.4% vs 16.9% NCT02376790
- 39.2% vs 16.9% NCT02376790
- 31.3% vs 15.1% NCT02376790
- 30.1% vs 15.1% NCT02376790
- 16.5% vs 6% NCT02376790
- 18.8% vs 6% NCT02376790
PASI 75
- adalimumab
- —Not posted · NCT00646178
- etanercept
- —Not posted · NCT00317499
Minimal disease activity
- adalimumab
- 41.5% vs 13.1%vs MTXNCT02814175
7 other results
- 53.8% vs 52.4% NCT03739853
- 46.2% vs 36.5% NCT03739853
- 54.9% vs 66.7% NCT02814175
- 80.4% vs 66.7% NCT02814175
- 29.8% vs 66.7% NCT02814175
- 55.4% vs 57.1% NCT03739853
- 64.6% vs 63.5% NCT03739853
- etanercept
- 51.3% vs 35.8%vs MethotrexateNCT02376790
13 other results
- 53.2% vs 35.8% NCT02376790
- 43.5% vs 30.3% NCT02376790
- 46.7% vs 30.3% NCT02376790
- 35.9% vs 22.9% NCT02376790
- 35.7% vs 22.9% NCT02376790
- 39.5% vs 25.7% NCT02376790
- 39.1% vs 25.7% NCT02376790
- 29.9% vs 11.6% NCT02376790
- 29.1% vs 11.6% NCT02376790
- 9.4% vs 3% NCT02376790
- 7.4% vs 3% NCT02376790
- 11.1% vs 5.7% NCT02376790
- 12.6% vs 5.7% NCT02376790
HAQ-DI, change
- adalimumab
- -0.5 vs -0.3vs MTXNCT02814175
- etanercept
- -0.5 vs -0.4vs MethotrexateNCT02376790
15 other results
- -0.5 vs -0.4 NCT02376790
- -0.4 vs -0.3 NCT02376790
- -0.5 vs -0.3 NCT02376790
- -0.4 vs -0.3 NCT02376790
- -0.4 vs -0.3 NCT02376790
- -0.4 vs -0.4 NCT02376790
- -0.5 vs -0.4 NCT02376790
- -0.4 vs -0.4 NCT02376790
- -0.5 vs -0.4 NCT02376790
- -0.3 vs -0.2 NCT02376790
- -0.3 vs -0.2 NCT02376790
- -0.5 vs -0.5 NCT02376790
- -0.5 vs -0.5 NCT02376790
- -0.6 vs -0.5 NCT02376790
- -0.6 vs -0.5 NCT02376790
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. adalimumab: 5 of 5 rows · etanercept: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | etanercept |
|---|---|---|
| DAS28-CRP absolute change · score | -2 vs -0.9 MTX score @ 16wka,b NCT02814175 · Phase 4 · registry result, not featured evidence · combination | -1.92 vs -1.47 Methotrexate score @ 16wkc,a,b NCT02376790 · Phase 3 · combination show 1 more dose-1.9 vs -1.47 Methotrexate score @ 16wk NCT02376790 · Phase 3 · monotherapy |
| Dropout rate | 4.6%d NCT03739853 · Phase 4 · registry result, not featured evidence show 4 more results4.9%Part 1: ADA + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination —Part 2: ADA NCT02814175 · Phase 4 · registry result, not featured evidence —Part 2: ADA + MTX Escalated Dose NCT02814175 · Phase 4 · registry result, not featured evidence · combination —Part 2: ADA ew + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination | 18.7%Etanercept + Methotrexated NCT02376790 · Phase 3 · combination show 5 more results16.5%Etanercept Monotherapy NCT02376790 · Phase 3 · monotherapy 35.5% NCT00127842 · Phase 4 · registry result, not featured evidence 4%BIW/QW NCT00245960 · Phase 4 · registry result, not featured evidence 2.9%QW/QW NCT00245960 · Phase 4 · registry result, not featured evidence — NCT02986139 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —d NCT03739853 · Phase 4 · registry result, not featured evidence show 4 more results2.4%Part 1: ADA + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination —Part 2: ADA NCT02814175 · Phase 4 · registry result, not featured evidence —Part 2: ADA + MTX Escalated Dose NCT02814175 · Phase 4 · registry result, not featured evidence · combination —Part 2: ADA ew + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination | —Etanercept + Methotrexated NCT02376790 · Phase 3 · combination show 5 more results—Etanercept Monotherapy NCT02376790 · Phase 3 · monotherapy 13.6% NCT00127842 · Phase 4 · registry result, not featured evidence 1.6%BIW/QW NCT00245960 · Phase 4 · registry result, not featured evidence 1.9%QW/QW NCT00245960 · Phase 4 · registry result, not featured evidence — NCT02986139 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 3.1%d NCT03739853 · Phase 4 · registry result, not featured evidence show 4 more results1.6%Part 1: ADA + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination 1.9%Part 2: ADA NCT02814175 · Phase 4 · registry result, not featured evidence 3.2%Part 2: ADA + MTX Escalated Dose NCT02814175 · Phase 4 · registry result, not featured evidence · combination 4.8%Part 2: ADA ew + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination | 6%Etanercept + Methotrexated NCT02376790 · Phase 3 · combination show 5 more results6.7%Etanercept Monotherapy NCT02376790 · Phase 3 · monotherapy 12.7% NCT00127842 · Phase 4 · registry result, not featured evidence —BIW/QW NCT00245960 · Phase 4 · registry result, not featured evidence —QW/QW NCT00245960 · Phase 4 · registry result, not featured evidence 0.9% NCT02986139 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | d liver function test abnormalities 27.7% nausea 23.1% diarrhoea 9.2% NCT03739853 · Phase 4 · registry result, not featured evidence show 4 more resultsheadache 8.1% upper respiratory tract infection 8.1% cough 5.7% NCT02814175 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 3.7% alanine aminotransferase increased 1.9% back pain 1.9% NCT02814175 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 13.7% nasopharyngitis 6.3% nausea 4.2% NCT02814175 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 14.3% back pain 6.3% psoriatic arthropathy 6.3% NCT02814175 · Phase 4 · registry result, not featured evidence · combination | d nausea 14.4% nasopharyngitis 9.5% upper respiratory tract infection 8.1% NCT02376790 · Phase 3 · combination show 5 more resultsnasopharyngitis 7.4% nausea 6.4% upper respiratory tract infection 6.4% NCT02376790 · Phase 3 · monotherapy nasopharyngitis 18.2% upper respiratory tract infection 13.6% injection site reaction 11.8% NCT00127842 · Phase 4 · registry result, not featured evidence BIW/QW upper respiratory infection 13.2% skin and appendages general disorders 11.9% digestive general disorders 10% NCT00245960 · Phase 4 · registry result, not featured evidence QW/QW skin and appendages general disorders 11% digestive general disorders 9.9% upper respiratory infection 9.7% NCT00245960 · Phase 4 · registry result, not featured evidence hypoaesthesia 1.9% pain in extremity 1.9% cellulitis 0.9% NCT02986139 · Phase 3 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 1 more result
show 3 more results
+ 4 further endpoints in the CSV export.
etanercept
show 15 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 7 more results
show 13 more results
show 13 more results
+ 20 further endpoints in the CSV export.
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195676 · Phase 3 · completed
Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.
Next expected readout: April 2028 · NCT07529925 (registry estimate)
Reported efficacy
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed) (not_applicable)
Result source: NCT00195676
etanercept · Enbrel
Marketed by Amgen and partners
NCT00111436 · Phase 3 · completed
Participants in this study had already been randomized in an earlier controlled trial and continued on etanercept here as an open-label extension to gather longer-term safety data, rather than as a fresh randomized comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Subject incidence of adverse events, including infectious episodes" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: June 2030 · NCT07352566 (registry estimate)
Reported efficacy
Subject incidence of adverse events, including infectious episodes (72 weeks); Changes from baseline in laboratory values (72 weeks): Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases. (not_applicable)
Result source: NCT00111436
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | etanercept |
|---|---|---|
| PASI 75 | 77.8% vs 11.5%+66.3 vs placeboNCT016460737 other results
| 57% vs 11%+46 vs placeboNCT000788192 other results
|
| PASI 90 | 61.8% vs 54.2%vs EU RPPNCT025813453 other results
| 27% vs 7%+20 vs placeboNCT00078819 |
| PASI 100 | 18.4% vs 2.7%vs MethotrexateNCT012516142 other results
| —Not posted · NCT00111449 |
| sPGA 0/1 | 60.5% vs 40.5%vs MethotrexateNCT0125161411 other results
| 28.9% vs 3.6%+25.3 vs placeboNCT016902992 other results
|
| DLQI, change | -4.8 vs -4.2−0.6 vs placeboNCT007357873 other results
| -7.8 vs -3.9−3.9 vs placeboNCT01690299 |
PASI 75
- adalimumab
- 77.8% vs 11.5%+66.3 vs placeboNCT01646073
7 other results
- 80.1% vs 79% NCT02581345
- 57.9% vs 32.4% NCT01251614
- 43.6% vs 32.4% NCT01251614
- 45.3% vs 2.3% NCT01646073
- 9.8% vs 0% NCT01646073
- 30.6% vs 8.7% NCT00735787
- 67% vs 27% NCT00932113
- etanercept
- 57% vs 11%+46 vs placeboNCT00078819
2 other results
- 48.2% vs 11.9% NCT01690299
- 63.3% vs 26.3% NCT03073200
PASI 90
- adalimumab
- 61.8% vs 54.2%vs EU RPPNCT02581345
3 other results
- 28.9% vs 21.6% NCT01251614
- 30.8% vs 21.6% NCT01251614
- 20.4% vs 0% NCT00735787
- etanercept
- 27% vs 7%+20 vs placeboNCT00078819
PASI 100
- adalimumab
- 18.4% vs 2.7%vs MethotrexateNCT01251614
2 other results
- 10.3% vs 2.7% NCT01251614
- 14.3% vs 0% NCT00735787
- etanercept
- —Not posted · NCT00111449
sPGA 0/1
- adalimumab
- 60.5% vs 40.5%vs MethotrexateNCT01251614
11 other results
- 41% vs 40.5% NCT01251614
- 80.5% vs 14.9% NCT01646073
- 57.4% vs 4.6% NCT01646073
- 20.1% vs 0% NCT01646073
- 68.9% vs 66.1% NCT02581345
- 30.6% vs 4.3% NCT00735787
- 28.6% vs 13% NCT00735787
- 24.5% vs 8.7% NCT00735787
- 20.4% vs 4.3% NCT00735787
- 8.2% vs 4.3% NCT00735787
- 73% vs 27% NCT00932113
- etanercept
- 28.9% vs 3.6%+25.3 vs placeboNCT01690299
2 other results
- 53% vs 13% NCT00078819
- 53.3% vs 5.3% NCT03073200
DLQI, change
- adalimumab
- -4.8 vs -4.2−0.6 vs placeboNCT00735787
3 other results
- -7.9 vs -3.7 NCT01553058
- -4.1 vs -3.1 NCT00735787
- -4.3 vs -3.4 NCT00735787
- etanercept
- -7.8 vs -3.9−3.9 vs placeboNCT01690299
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
14 other shared endpoints and safety
Coverage. adalimumab: 18 of 18 rows · etanercept: 18 of 18 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | etanercept Rows use multiple source trials |
|---|---|---|
| DLQI absolute change · score Maintenance | -5.18 vs -4.74 placebo score @ 28wka,b,c NCT00735787 · Phase 4 · registry result, not featured evidence | -0.4 vs 2 placebo score @ 24wka,b,c NCT00581555 · Phase 4 · registry result, not featured evidence |
| DLQI percent change · % of baseline No placebo or comparator arm | -79.16% (n=49) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence | 36.95% (n=75) @ 24wka,b NCT02749370 · Phase 4 · registry result, not featured evidence |
| DLQI absolute change · score No placebo or comparator arm | -4.8 score @ 24wkd,a,b NCT02533375 · Phase 3 · registry result, not featured evidence | -10.5 score @ 24wk50 mg BW/QWe,d,a,b NCT00663052 · Phase 4 · registry result, not featured evidence show 1 more dose-9.2 score @ 24wk50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence |
| PASI percent change · % of baseline Maintenance | -86.43% (n=246) vs -85.53% (n=120) EU RPP @ 52wkd,a,b,f NCT02581345 · Phase 3 · registry result, not featured evidence | -13.3% (n=38) vs 121.9% (n=19) placebo @ 24wkd,a,b,f NCT00581555 · Phase 4 · registry result, not featured evidence |
| PASI absolute change · score Maintenance | -9 vs -0.9 placebo score @ 26wkEOWd,a,b,g NCT02016482 · Phase 3 · registry result, not featured evidence | -1.8 vs 2.9 placebo score @ 24wkd,a,b,g NCT00581555 · Phase 4 · registry result, not featured evidence |
| PASI percent change · % of baseline No placebo or comparator arm | -91.18% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence 2 other source trials-43.6% (n=10) @ 24wk NCT02533375 · Phase 3 · registry result, not featured evidence -91.07% (n=333) @ 24wkEow NCT01646073 · Phase 3 · registry result, not featured evidence | 57.67% (n=77) @ 24wka,b NCT02749370 · Phase 4 · registry result, not featured evidence 2 other source trials0.86% (n=140) @ 24wk50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination 72.56% (n=143) @ 24wk50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination |
| PASI absolute change · score No placebo or comparator arm | -16.8 score @ 24wkd,a,b NCT02533375 · Phase 3 · registry result, not featured evidence | -17.4 score @ 24wk50 mg BW/QWe,d,a,b NCT00663052 · Phase 4 · registry result, not featured evidence show 1 more dose-15.4 score @ 24wk50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence |
| PASI 100 responder rate · % of participants No placebo or comparator arm | 64% (n=50) @ 24wka NCT01644396 · Phase 4 · registry result, not featured evidence | 5.3% (n=38) @ 24wk*e,a NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted show 3 more doses6.9% (n=29) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted 5.4% (n=37) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted 14.3% (n=7) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted |
| PASI 50 responder rate · % of participants Induction | 42.9% (n=49) vs 21.7% (n=23) placebo @ 16wk*h,i,b NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 21 subjects as posted 1 other source trial91% (n=267) vs 93.4% (n=271) EU RPP @ 16wk* NCT02581345 · Phase 3 · registry result, not featured evidence · converted to % from 243 Participants as posted | 83.1% (n=83) vs 33.3% (n=84) placebo @ 16wk50 mg SC QWh,i,b NCT01690299 · Phase 3 · registry result, not featured evidence |
| PASI 50 responder rate · % of participants No placebo or comparator arm | 96% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence 3 other source trials40% (n=10) @ 24wk* NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted 89.9% (n=89) @ 24wk*40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 80 Participants as posted 94.8% (n=58) @ 24wk*80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 55 Participants as posted | 62.3% (n=77) @ 24wka,b NCT02749370 · Phase 4 · registry result, not featured evidence 5 other source trials92.5% (n=133) @ 24wk50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 81% (n=137) @ 24wk50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 84.38% (n=33) @ 24wkOnce Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 85.71% (n=36) @ 24wkTwice, Then Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 88.7% (n=143) @ 24wk50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination |
| PASI 75 responder rate · % of participants No placebo or comparator arm | 82% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence 4 other source trials40% (n=10) @ 24wk* NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted 87.7% (n=333) @ 24wkEow NCT01646073 · Phase 3 · registry result, not featured evidence 77.5% (n=89) @ 24wk*40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 69 Participants as posted 86.2% (n=58) @ 24wk*80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 50 Participants as posted | 45.5% (n=77) @ 24wka,b NCT02749370 · Phase 4 · registry result, not featured evidence 13 other source trials44.7% (n=38) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 17 Participants as posted 55.2% (n=29) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 16 Participants as posted 51.4% (n=37) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted 100% (n=7) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted 78.2% (n=133) @ 24wk50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 78.2% (n=133) @ 24wk50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 59.9% (n=137) @ 24wk50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 59.9% (n=137) @ 24wk50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 62.5% (n=33) @ 24wkOnce Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 77.14% (n=36) @ 24wkTwice, Then Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 60.3% (n=143) @ 24wk50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination 69.3% (n=295) @ 24wk NCT01235442 · Phase 3 · registry result, not featured evidence · combination 63.6% (n=297) @ 24wk NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy |
| PASI 90 responder rate · % of participants No placebo or comparator arm | 76% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence 3 other source trials10% (n=10) @ 24wk* NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted 56.2% (n=89) @ 24wk*40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 50 Participants as posted 67.2% (n=58) @ 24wk*80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 39 Participants as posted | 22.1% (n=77) @ 24wka,b NCT02749370 · Phase 4 · registry result, not featured evidence 7 other source trials15.8% (n=38) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted 20.7% (n=29) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted 16.2% (n=37) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted 42.9% (n=7) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 49.6% (n=133) @ 24wk50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 32.8% (n=137) @ 24wk50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 27% (n=143) @ 24wk50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination |
| PGA =0 responder rate · % of participants No placebo or comparator arm | 70% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence 1 other source trial45.6% (n=333) @ 24wkEow NCT01646073 · Phase 3 · registry result, not featured evidence | 21.1% (n=133) @ 24wk50 mg BW/QWe,a,b NCT00663052 · Phase 4 · registry result, not featured evidence show 1 more dose12.4% (n=137) @ 24wk50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence |
| sPGA 0/1 responder rate · % of participants No placebo or comparator arm | 80% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence 3 other source trials83.8% (n=333) @ 24wkEow NCT01646073 · Phase 3 · registry result, not featured evidence 32.3% (n=31) @ 24wk*40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 10 Participants as posted 30.4% (n=23) @ 24wk*40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted | 33.8% (n=77) @ 24wka,b NCT02749370 · Phase 4 · registry result, not featured evidence 11 other source trials34.2% (n=38) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted 37.9% (n=29) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted 32.4% (n=37) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 12 Participants as posted 100% (n=7) @ 24wk* NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted 69.9% (n=133) @ 24wk50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 50.4% (n=137) @ 24wk50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 75% (n=32) @ 24wkOnce Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 68.57% (n=35) @ 24wkTwice, Then Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 45.4% (n=143) @ 24wk50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination 61.7% (n=295) @ 24wk NCT01235442 · Phase 3 · registry result, not featured evidence · combination 54.8% (n=297) @ 24wk NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy |
| Dropout rate | 41.3%j NCT00195676 · Phase 3 show 35 more results6.7% NCT00932113 · Phase 4 · registry result, not featured evidence 3% NCT01553058 · Phase 4 · registry result, not featured evidence 0% NCT01644396 · Phase 4 · registry result, not featured evidence 4.7% NCT01265823 · Phase 4 · registry result, not featured evidence 16.3% NCT00735787 · Phase 4 · registry result, not featured evidence 9.4% NCT05637515 · Phase 3 · registry result, not featured evidence 50% NCT02533375 · Phase 3 · registry result, not featured evidence 5.2%Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 13.8%EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 21.1%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 33.3%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 1.5%Eow NCT01646073 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 11%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 4.9%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 17.2%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence 2%Group A NCT00927069 · Phase 3 · registry result, not featured evidence 2.9%Group B NCT00927069 · Phase 3 · registry result, not featured evidence 7.7%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 7.1%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence 11.8%40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence 22.4%80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 24.7%40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 0% NCT01872546 · Phase 2 · registry result, not featured evidence 11.1% NCT01320293 · Phase na · registry result, not featured evidence | —0.8 mg/kg QWj NCT00078819 · Phase 3 show 35 more results—0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 0.9%Etanercept NCT00078819 · Phase 3 17.5% NCT02749370 · Phase 4 · registry result, not featured evidence 16% NCT01971346 · Phase 4 · registry result, not featured evidence 18.9% NCT02274792 · Phase 4 · registry result, not featured evidence 16.3% NCT00992394 · Phase 4 · registry result, not featured evidence 0% NCT01053819 · Phase 4 · registry result, not featured evidence 5.1%Part 1 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence —Part 2 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence —Part 2 - Etanercept and nbUVB NCT00640393 · Phase 4 · registry result, not featured evidence · combination 6.5%50 mg BIW/QW NCT00791765 · Phase 4 · registry result, not featured evidence 27.6% NCT00332332 · Phase 4 · registry result, not featured evidence 8.8%50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 7.3%50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 34.5% NCT00581555 · Phase 4 · registry result, not featured evidence 14.7%Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 18.4%Twice, Then Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 27.7%Continuous NCT00195507 · Phase 4 · registry result, not featured evidence 32.5%Intermittent NCT00195507 · Phase 4 · registry result, not featured evidence 0% NCT03073200 · Phase 3 · registry result, not featured evidence 77.5% NCT00141921 · Phase 3 · registry result, not featured evidence 2.4%50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence —50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence 5.6%50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination —Etanercept Monotherapy NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy 14.9%Etanercept + Clobetasol Propionate NCT01235442 · Phase 3 · registry result, not featured evidence · combination 14.8%Etanercept Monotherapy NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy 7.2%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 9.3%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 0%50 mg twice weekly NCT00585650 · Phase 1/2 · registry result, not featured evidence 33.3% NCT01170715 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 5.6%j NCT00195676 · Phase 3 show 35 more results— NCT00932113 · Phase 4 · registry result, not featured evidence — NCT01553058 · Phase 4 · registry result, not featured evidence — NCT01644396 · Phase 4 · registry result, not featured evidence — NCT01265823 · Phase 4 · registry result, not featured evidence — NCT00735787 · Phase 4 · registry result, not featured evidence — NCT05637515 · Phase 3 · registry result, not featured evidence 20% NCT02533375 · Phase 3 · registry result, not featured evidence 1%Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 4.6%EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 2.6%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0.6%Eow NCT01646073 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 6.9%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —Group A NCT00927069 · Phase 3 · registry result, not featured evidence —Group B NCT00927069 · Phase 3 · registry result, not featured evidence 4.9%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 1.6%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence —40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence —80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence —40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence — NCT01872546 · Phase 2 · registry result, not featured evidence 5.6% NCT01320293 · Phase na · registry result, not featured evidence | —0.8 mg/kg QWj NCT00078819 · Phase 3 show 35 more results—0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 0.9%Etanercept NCT00078819 · Phase 3 — NCT02749370 · Phase 4 · registry result, not featured evidence — NCT01971346 · Phase 4 · registry result, not featured evidence — NCT02274792 · Phase 4 · registry result, not featured evidence 5.8% NCT00992394 · Phase 4 · registry result, not featured evidence — NCT01053819 · Phase 4 · registry result, not featured evidence —Part 1 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence —Part 2 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence —Part 2 - Etanercept and nbUVB NCT00640393 · Phase 4 · registry result, not featured evidence · combination 1.6%50 mg BIW/QW NCT00791765 · Phase 4 · registry result, not featured evidence 5.3% NCT00332332 · Phase 4 · registry result, not featured evidence 4.4%50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 2.2%50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 5.2% NCT00581555 · Phase 4 · registry result, not featured evidence 2.9%Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 5.3%Twice, Then Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 6.7%Continuous NCT00195507 · Phase 4 · registry result, not featured evidence 3.6%Intermittent NCT00195507 · Phase 4 · registry result, not featured evidence — NCT03073200 · Phase 3 · registry result, not featured evidence 2.7% NCT00141921 · Phase 3 · registry result, not featured evidence 1.2%50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence —50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence 0%50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination —Etanercept Monotherapy NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy 2%Etanercept + Clobetasol Propionate NCT01235442 · Phase 3 · registry result, not featured evidence · combination 1.3%Etanercept Monotherapy NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy 2.4%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 6.5%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence —50 mg twice weekly NCT00585650 · Phase 1/2 · registry result, not featured evidence — NCT01170715 · Phase na · registry result, not featured evidence |
| Serious AEs | 12.9%j NCT00195676 · Phase 3 show 35 more results0% NCT00932113 · Phase 4 · registry result, not featured evidence 6.1% NCT01553058 · Phase 4 · registry result, not featured evidence 0% NCT01644396 · Phase 4 · registry result, not featured evidence 0.7% NCT01265823 · Phase 4 · registry result, not featured evidence 4.1% NCT00735787 · Phase 4 · registry result, not featured evidence 1.7% NCT05637515 · Phase 3 · registry result, not featured evidence 30% NCT02533375 · Phase 3 · registry result, not featured evidence —Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 1.4%Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 3.7%Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 7.3%EOW NCT02016482 · Phase 3 · registry result, not featured evidence 3.2%EOW NCT02016482 · Phase 3 · registry result, not featured evidence 0%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 5.7%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 7.7%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 1.2%Eow NCT01646073 · Phase 3 · registry result, not featured evidence 4.9%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 3.4%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence 0%Group A NCT00927069 · Phase 3 · registry result, not featured evidence 0%Group B NCT00927069 · Phase 3 · registry result, not featured evidence 4.4%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 4.1%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence —40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence 19%80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 21.3%40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 0% NCT01872546 · Phase 2 · registry result, not featured evidence 5.6% NCT01320293 · Phase na · registry result, not featured evidence | 0%0.8 mg/kg QWj NCT00078819 · Phase 3 show 35 more results0%0.8 mg/kg QW NCT00078819 · Phase 3 0%0.8 mg/kg QW NCT00078819 · Phase 3 0%0.8 mg/kg QW NCT00078819 · Phase 3 0%0.8 mg/kg QW NCT00078819 · Phase 3 0%0.8 mg/kg QW NCT00078819 · Phase 3 —Etanercept NCT00078819 · Phase 3 2.5% NCT02749370 · Phase 4 · registry result, not featured evidence 2.2% NCT01971346 · Phase 4 · registry result, not featured evidence 3.8% NCT02274792 · Phase 4 · registry result, not featured evidence 4.8% NCT00992394 · Phase 4 · registry result, not featured evidence 0% NCT01053819 · Phase 4 · registry result, not featured evidence 1%Part 1 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence 5.3%Part 2 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence 0%Part 2 - Etanercept and nbUVB NCT00640393 · Phase 4 · registry result, not featured evidence · combination 3.4%50 mg BIW/QW NCT00791765 · Phase 4 · registry result, not featured evidence 5.2% NCT00332332 · Phase 4 · registry result, not featured evidence 2.2%50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 2.9%50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 3.4% NCT00581555 · Phase 4 · registry result, not featured evidence 0%Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 5.3%Twice, Then Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence —Continuous NCT00195507 · Phase 4 · registry result, not featured evidence —Intermittent NCT00195507 · Phase 4 · registry result, not featured evidence 3.3% NCT03073200 · Phase 3 · registry result, not featured evidence 3.9% NCT00141921 · Phase 3 · registry result, not featured evidence —50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence 2.4%50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence —50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination 2.3%Etanercept Monotherapy NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy 2.4%Etanercept + Clobetasol Propionate NCT01235442 · Phase 3 · registry result, not featured evidence · combination 2%Etanercept Monotherapy NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy 2.9%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 2.4%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 0%50 mg twice weekly NCT00585650 · Phase 1/2 · registry result, not featured evidence 9.5% NCT01170715 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | show 29 more resultsupper respiratory tract infection 40% dizziness 13.3% flu-like symptoms 13.3% NCT00932113 · Phase 4 · registry result, not featured evidence upper respiratory infection 9.1% (placebo 12.9%) joint range of motion decrease 6.1% (placebo 0%) headache 3% (placebo 6.5%) NCT01553058 · Phase 4 · registry result, not featured evidence latent tuberculosis 8% rhinitis 6% alanine aminotransferase increased 2% NCT01644396 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 11.3% hyperglycemia 10.7% arthralgia 6.7% NCT01265823 · Phase 4 · registry result, not featured evidence nasopharyngitis 26.5% (placebo 13%) headache 14.3% (placebo 4.3%) cough 8.2% (placebo 4.3%) NCT00735787 · Phase 4 · registry result, not featured evidence headache 2.2% nasopharyngitis 2.2% upper respiratory tract infection 2.2% NCT05637515 · Phase 3 · registry result, not featured evidence nasopharyngitis 30% pruritus 30% hypoalbuminaemia 20% NCT02533375 · Phase 3 · registry result, not featured evidence injection site reaction 23.9% nasopharyngitis 6.7% headache 3.2% NCT02581345 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.8% psoriasis 10.3% injection site reaction 10% NCT02581345 · Phase 3 · registry result, not featured evidence EOW upper respiratory tract infection 8.3% (placebo 8.3%) headache 5.5% (placebo 0%) nasopharyngitis 5.5% (placebo 9.3%) NCT02016482 · Phase 3 · registry result, not featured evidence EOW nasopharyngitis 12.8% (placebo 9.3%) upper respiratory tract infection 4.3% (placebo 8.3%) depression 3.2% (placebo 0.9%) NCT02016482 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 21.1% headache 15.8% dry skin 7.9% NCT01251614 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 18.5% back pain 11.1% headache 11.1% NCT01251614 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 28.7% headache 25.3% upper respiratory tract infection 14.9% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg nasopharyngitis 25.6% headache 17.9% cough 10.3% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg cough 18.2% decreased appetite 9.1% gastroenteritis 9.1% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg nasopharyngitis 23.1% agitation 7.7% cough 7.7% NCT01251614 · Phase 3 · registry result, not featured evidence Eow upper respiratory tract infection 10.1% (placebo 6.9%) oropharyngeal pain 4.1% (placebo 1.1%) nasopharyngitis 3.8% (placebo 5.7%) NCT01646073 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 6.1% cough 3.7% headache 3.7% NCT00566722 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 12.2% injection site erythema 7.3% nasopharyngitis 7.3% NCT00566722 · Phase 3 · registry result, not featured evidence fatigue 6.9% pharyngitis 6.9% abdominal pain 3.4% NCT00566722 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18% back pain 8% common cold 8% NCT00927069 · Phase 3 · registry result, not featured evidence headache 11.4% common cold 5.7% upper respiratory tract infection 5.7% NCT00927069 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.7% headache 5.2% psoriasis 5.2% NCT00574249 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.3% headache 6% pruritus 5.8% NCT00574249 · Phase 3 · registry result, not featured evidence 40 mg Eow nasopharyngitis 10.8% upper respiratory tract infection 10.8% headache 4.9% NCT00513370 · Phase 3 · registry result, not featured evidence 80 mg every other week nasopharyngitis 77.6% blood triglycerides increased 29.3% blood creatine phosphokinase increased 25.9% NCT00647400 · Phase 2/3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 75.3% blood triglycerides increased 24.7% alanine aminotransferase increased 23.6% NCT00647400 · Phase 2/3 · registry result, not featured evidence upper respiratory tract infection 22.2% elbow strain 5.6% heartburn 5.6% NCT01320293 · Phase na · registry result, not featured evidence | 0.8 mg/kg QWj upper respiratory tract infection 12.5% (placebo 11.4%) skin papilloma 6.3% (placebo 0%) acne 3.1% (placebo 0%) NCT00078819 · Phase 3 show 31 more results0.8 mg/kg QW upper respiratory tract infection 17% (placebo 11.4%) headache 13.2% (placebo 12.4%) influenza 7.5% (placebo 1.9%) NCT00078819 · Phase 3 0.8 mg/kg QW upper respiratory tract infection 42.4% (placebo 11.4%) headache 20.3% (placebo 12.4%) nasopharyngitis 20.3% (placebo 8.6%) NCT00078819 · Phase 3 0.8 mg/kg QW upper respiratory tract infection 30.8% (placebo 11.4%) headache 20.2% (placebo 12.4%) nasopharyngitis 18.8% (placebo 8.6%) NCT00078819 · Phase 3 0.8 mg/kg QW upper respiratory tract infection 25% (placebo 11.4%) abdominal pain 8.3% (placebo 0%) body tinea 8.3% (placebo 0%) NCT00078819 · Phase 3 0.8 mg/kg QW nasopharyngitis 10.3% (placebo 8.6%) headache 8.8% (placebo 12.4%) acne 2.9% (placebo 0%) NCT00078819 · Phase 3 back pain 2.5% exostosis 2.5% injection related reaction 2.5% NCT02749370 · Phase 4 · registry result, not featured evidence nasal congestion 8.7% gi distress 6.5% injection site reaction 6.5% NCT01971346 · Phase 4 · registry result, not featured evidence injection site reaction 7.6% psoriasis 6.1% headache 5.3% NCT02274792 · Phase 4 · registry result, not featured evidence nasopharyngitis 26.2% bronchitis 10.7% arthralgia 7.1% NCT00992394 · Phase 4 · registry result, not featured evidence common cold 9.1% injection site reaction 4% upper respiratory tract infection 4% NCT00640393 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 15.8% common cold 13.2% injection site reaction 0% NCT00640393 · Phase 4 · registry result, not featured evidence common cold 5.4% upper respiratory tract infection 2.7% injection site reaction 0% NCT00640393 · Phase 4 · registry result, not featured evidence · combination 50 mg BIW/QW nasopharyngitis 8.5% (placebo 8.1%) upper respiratory tract infection 8.5% (placebo 14.5%) arthralgia 6.8% (placebo 3.2%) NCT00791765 · Phase 4 · registry result, not featured evidence nasopharyngitis 7.8% headache 7% upper respiratory tract infection 7% NCT00332332 · Phase 4 · registry result, not featured evidence 50 mg BW/QW headache 11% nasopharyngitis 10.3% upper respiratory tract infection 6.6% NCT00663052 · Phase 4 · registry result, not featured evidence 50 mg QW/QW nasopharyngitis 16.1% headache 10.9% diarrhoea 7.3% NCT00663052 · Phase 4 · registry result, not featured evidence headache 29.3% (placebo 33.9%) nasopharyngitis 19% (placebo 21%) hypertension 15.5% (placebo 14.5%) NCT00581555 · Phase 4 · registry result, not featured evidence Once Weekly nasopharyngitis 11.8% headache nos 8.8% alopecia areata 2.9% NCT00581100 · Phase 4 · registry result, not featured evidence Twice, Then Once Weekly headache nos 10.5% nasopharyngitis 10.5% dermatitis allergic 5.3% NCT00581100 · Phase 4 · registry result, not featured evidence upper respiratory infection 17.9% headache 17.6% nervous 13.4% NCT00195507 · Phase 4 · registry result, not featured evidence upper respiratory infection 17.4% headache 12.9% arthralgia 11% NCT00195507 · Phase 4 · registry result, not featured evidence influenza 6.7% (placebo 0%) pharyngitis 6.7% (placebo 0%) bronchitis 3.3% (placebo 0%) NCT03073200 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 37.6% nasopharyngitis 26% headache 21.5% NCT00141921 · Phase 3 · registry result, not featured evidence 50 mg SC QW nasopharyngitis 9.6% (placebo 9.5%) headache 6% (placebo 3.6%) cough 4.8% (placebo 3.6%) NCT01690299 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.7% injection site reaction 9% NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy nasopharyngitis 8.3% upper respiratory tract infection 6.9% sinusitis 6.3% NCT01235442 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 11.6% nasopharyngitis 8.6% headache 7.3% NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy 50 mg nasopharyngitis 11.6% injection site reaction 8.7% headache 6.3% NCT00482170 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 12.8% injection site erythema 8.1% injection site reaction 8.1% NCT00482170 · Phase 3 · registry result, not featured evidence 50 mg twice weekly upper respiratory infection 37.5% (placebo 33.3%) NCT00585650 · Phase 1/2 · registry result, not featured evidence upper respiratory infection 28.6% fatigue 9.5% rash 9.5% NCT01170715 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 28 weeks versus 24 weeks.
- dTrial phases differ: Phase 3 versus Phase 4.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fAssessment timepoints differ: 52 weeks versus 24 weeks.
- gAssessment timepoints differ: 26 weeks versus 24 weeks.
- hTrial phases differ: Phase 4 versus Phase 3.
- iPopulation context differs: registered conditions differ.
- jPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 5 more results
show 2 more results
show 1 more result
+ 163 further endpoints in the CSV export.
etanercept
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 24 more results
show 8 more results
show 19 more results
show 19 more results
+ 33 further endpoints in the CSV export.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195702 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).
Next expected readout: December 2027 · NCT06440629 (registry estimate)
Reported efficacy
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)
Result source: NCT00195702
etanercept · Enbrel
Marketed by Amgen and partners
NCT03780959 · Phase 2/3 · completed
After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
Reported efficacy
Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81% (met)
Result source: NCT03780959
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | etanercept |
|---|---|---|
| ACR20 | 63.3% vs 29.5%+33.8 vs placeboNCT0019570228 other results
| 78.6% vs 62.5%vs MethotrexateNCT0044577063 other results
|
| ACR50 | 41.2% vs 45.9%vs MethotrexateNCT0019566319 other results
| 62.1% vs 36.9%vs MethotrexateNCT0044577065 other results
|
| ACR70 | 47.4% vs 22.7%+24.7 vs placeboNCT0087046716 other results
| 36.3% vs 15.9%vs MethotrexateNCT0044577064 other results
|
| DAS28-CRP remission | 38.5% vs 42.9%vs Standard of CareNCT011624215 other results
| 54.5% vs 69.1%vs Standard COBRA-Slim InductionNCT036490611 other result
|
| HAQ-DI, change | -0.6 vs -0.3−0.3 vs placeboNCT0019570222 other results
| -0.6 vs -0.3vs MethotrexateNCT0044577031 other results
|
| Modified Sharp score, change | 0.1 vs 2.7−2.6 vs placeboNCT0019570215 other results
| 3.3 vs 9.8vs MethotrexateNCT0044577011 other results
|
ACR20
- adalimumab
- 63.3% vs 29.5%+33.8 vs placeboNCT00195702
28 other results
- 50.3% vs 33.9% NCT00647270
- 57% vs 35% NCT00538902
- 47.3% vs 33.9% NCT00647270
- 51.2% vs 35% NCT00538902
- 60.8% vs 29.5% NCT00195702
- 58.9% vs 24% NCT00195702
- 54.7% vs 24% NCT00195702
- 75.4% vs 56.4% NCT00870467
- 50% vs 59.9% NCT00195663
- 69% vs 59.9% NCT00195663
- 54.4% vs 62.6% NCT00195663
- 72.8% vs 62.6% NCT00195663
- 49.3% vs 56% NCT00195663
- 69.4% vs 56% NCT00195663
- 53.3% vs 61.5% NCT00195663
- 68.7% vs 61.5% NCT00195663
- 69.2% vs 71.4% NCT01500278
- 84.8% vs 80.4% NCT00420927
- 66.4% vs 80.4% NCT00420927
- 64.5% vs 60.8% NCT01500278
- 68% vs 68% NCT01712178
- 62% vs 68% NCT01712178
- 51.3% vs 65.7% NCT01162421
- 56.4% vs 68.6% NCT01162421
- 46.2% vs 65.7% NCT01162421
- 66.7% vs 60% NCT01162421
- 64.1% vs 37.1% NCT01162421
- 69.2% vs 57.1% NCT01162421
- etanercept
- 78.6% vs 62.5%vs MethotrexateNCT00445770
63 other results
- 79.7% vs 59.1% NCT00445770
- 75.3% vs 59.7% NCT00445770
- 80.8% vs 58% NCT00445770
- 77.5% vs 56.3% NCT00445770
- 78.6% vs 58.5% NCT00445770
- 75.3% vs 51.7% NCT00445770
- 77.5% vs 48.3% NCT00445770
- 68.7% vs 43.2% NCT00445770
- 56.9% vs 27.3% NCT00445770
- 49.4% vs 16.1% NCT00445770
- 75.9% vs 62.5% NCT00445770
- 76.4% vs 59.1% NCT00445770
- 78.5% vs 59.7% NCT00445770
- 79.1% vs 58% NCT00445770
- 77% vs 56.3% NCT00445770
- 75.4% vs 58.5% NCT00445770
- 73.8% vs 51.7% NCT00445770
- 70.2% vs 48.3% NCT00445770
- 68.1% vs 43.2% NCT00445770
- 55.5% vs 27.3% NCT00445770
- 54% vs 16.1% NCT00445770
- 78% vs 47.2% NCT00565409
- 79.5% vs 46.7% NCT00565409
- 76.5% vs 48.7% NCT00565409
- 75.5% vs 48.7% NCT00565409
- 75% vs 50.3% NCT00565409
- 77% vs 50.3% NCT00565409
- 76.9% vs 61.2% NCT00565409
- 86.5% vs 88.3% NCT00565409
- 74.6% vs 47.2% NCT00565409
- 77.6% vs 46.7% NCT00565409
- 74.1% vs 48.7% NCT00565409
- 74.6% vs 48.7% NCT00565409
- 74.6% vs 50.3% NCT00565409
- 76.1% vs 50.3% NCT00565409
- 77.7% vs 61.2% NCT00565409
- 85.1% vs 88.3% NCT00565409
- 90.5% vs 61.5% NCT00913458
- 96.8% vs 67.7% NCT00913458
- 87.3% vs 47.7% NCT00913458
- 93.7% vs 86.2% NCT00913458
- 96.8% vs 98.5% NCT00913458
- 51.9% vs 54.8% NCT01313208
- 49.1% vs 47.1% NCT01313208
- 40.6% vs 28.8% NCT01313208
- 50% vs 23.1% NCT01313208
- 36.8% vs 19.2% NCT01313208
- 28.6% vs 14.9% NCT01313208
- 89.2% vs 87.3% NCT00848354
- 88.8% vs 91.3% NCT00848354
- 90.9% vs 89.2% NCT00848354
- 90% vs 86.5% NCT00848354
- 91.7% vs 90.8% NCT00848354
- 86.9% vs 81.0% NCT00848354
- 90.0% vs 83.3% NCT00848354
- 83.2% vs 50% NCT00848354
- 89.2% vs 89.2% NCT00848354
- 84.6% vs 58.5% NCT00848354
- 84.2% vs 57.8% NCT00848354
- 79.6% vs 54.9% NCT00848354
- 73.8% vs 49.3% NCT00848354
- 63.8% vs 34.5% NCT00848354
- 47.8% vs 19.3% NCT00848354
ACR50
- adalimumab
- 41.2% vs 45.9%vs MethotrexateNCT00195663
19 other results
- 61.6% vs 45.9% NCT00195663
- 64.3% vs 38.7% NCT00870467
- 41.6% vs 44.4% NCT00195663
- 60.1% vs 44.4% NCT00195663
- 36.9% vs 42.8% NCT00195663
- 59% vs 42.8% NCT00195663
- 35% vs 40.5% NCT00195663
- 58.6% vs 40.5% NCT00195663
- 78.1% vs 69.6% NCT00420927
- 46.3% vs 69.6% NCT00420927
- 48% vs 50% NCT01712178
- 36% vs 40% NCT01712178
- 38.5% vs 45.7% NCT01162421
- 43.6% vs 34.3% NCT01162421
- 33.3% vs 42.9% NCT01162421
- 48.7% vs 40% NCT01162421
- 43.6% vs 22.9% NCT01162421
- 38.5% vs 22.9% NCT01162421
- 64.7% vs 51.6% NCT03823391
- etanercept
- 62.1% vs 36.9%vs MethotrexateNCT00445770
65 other results
- 57.7% vs 39.2% NCT00445770
- 58.8% vs 36.9% NCT00445770
- 59.3% vs 34.7% NCT00445770
- 54.4% vs 32.4% NCT00445770
- 50.5% vs 30.7% NCT00445770
- 44% vs 26.1% NCT00445770
- 42.3% vs 23.9% NCT00445770
- 35.7% vs 15.3% NCT00445770
- 22.5% vs 4% NCT00445770
- 16% vs 2.3% NCT00445770
- 59.4% vs 36.9% NCT00445770
- 57.3% vs 39.2% NCT00445770
- 60.4% vs 36.9% NCT00445770
- 60.4% vs 34.7% NCT00445770
- 53.6% vs 32.4% NCT00445770
- 50% vs 30.7% NCT00445770
- 50% vs 26.1% NCT00445770
- 47.4% vs 23.9% NCT00445770
- 38.5% vs 15.3% NCT00445770
- 28.1% vs 4% NCT00445770
- 14.7% vs 2.3% NCT00445770
- 62.0% vs 23.2% NCT00848354
- 63% vs 26.9% NCT00565409
- 62.5% vs 27.4% NCT00565409
- 59% vs 27.9% NCT00565409
- 62.5% vs 25.9% NCT00565409
- 62% vs 28.9% NCT00565409
- 58% vs 33.5% NCT00565409
- 60.5% vs 41% NCT00565409
- 76.5% vs 74.1% NCT00565409
- 53.7% vs 26.9% NCT00565409
- 58.7% vs 27.4% NCT00565409
- 55.7% vs 27.9% NCT00565409
- 57.2% vs 25.9% NCT00565409
- 56.2% vs 28.9% NCT00565409
- 59.2% vs 33.5% NCT00565409
- 57.9% vs 41% NCT00565409
- 70.6% vs 74.1% NCT00565409
- 85.7% vs 50.8% NCT00913458
- 93.7% vs 50.8% NCT00913458
- 76.2% vs 44.6% NCT00913458
- 87.3% vs 73.8% NCT00913458
- 92.1% vs 95.4% NCT00913458
- 33% vs 28.8% NCT01313208
- 29.2% vs 28.8% NCT01313208
- 30.2% vs 22.1% NCT01313208
- 20.8% vs 12.5% NCT01313208
- 19.8% vs 4.8% NCT01313208
- 13.2% vs 4.8% NCT01313208
- 5.7% vs 3% NCT01313208
- 67.3% vs 58.7% NCT00848354
- 68.5% vs 62.7% NCT00848354
- 73.4% vs 60.8% NCT00848354
- 65.8% vs 60.3% NCT00848354
- 73.4% vs 61.7% NCT00848354
- 67.3% vs 53.2% NCT00848354
- 72.6% vs 59.2% NCT00848354
- 62.0% vs 23.2% NCT00848354
- 70.5% vs 65% NCT00848354
- 59.1% vs 27.5% NCT00848354
- 56.3% vs 24.6% NCT00848354
- 52.3% vs 21.1% NCT00848354
- 42.3% vs 16.9% NCT00848354
- 31.5% vs 8.4% NCT00848354
- 15.8% vs 2.9% NCT00848354
ACR70
- adalimumab
- 47.4% vs 22.7%+24.7 vs placeboNCT00870467
16 other results
- 28.8% vs 29.2% NCT00195663
- 47.4% vs 29.2% NCT00195663
- 25.9% vs 27.2% NCT00195663
- 45.5% vs 27.2% NCT00195663
- 28.1% vs 28.4% NCT00195663
- 46.6% vs 28.4% NCT00195663
- 19.7% vs 22.2% NCT00195663
- 42.5% vs 22.2% NCT00195663
- 69.5% vs 57.1% NCT00420927
- 30.1% vs 57.1% NCT00420927
- 30.8% vs 20% NCT01162421
- 30.8% vs 14.3% NCT01162421
- 23.1% vs 40% NCT01162421
- 25.6% vs 22.9% NCT01162421
- 28.2% vs 8.6% NCT01162421
- 15.4% vs 2.9% NCT01162421
- etanercept
- 36.3% vs 15.9%vs MethotrexateNCT00445770
64 other results
- 36.3% vs 18.2% NCT00445770
- 35.7% vs 14.8% NCT00445770
- 31.3% vs 11.9% NCT00445770
- 25.8% vs 11.9% NCT00445770
- 25.3% vs 13.1% NCT00445770
- 18.7% vs 9.7% NCT00445770
- 15.4% vs 9.7% NCT00445770
- 11% vs 2.8% NCT00445770
- 8.2% vs 0.6% NCT00445770
- 3.8% vs 0% NCT00445770
- 33.9% vs 15.9% NCT00445770
- 34.4% vs 18.2% NCT00445770
- 31.3% vs 14.8% NCT00445770
- 28.1% vs 11.9% NCT00445770
- 25.5% vs 11.9% NCT00445770
- 25% vs 13.1% NCT00445770
- 17.7% vs 9.7% NCT00445770
- 21.9% vs 9.7% NCT00445770
- 15.1% vs 2.8% NCT00445770
- 7.8% vs 0.6% NCT00445770
- 4.2% vs 0% NCT00445770
- 32% vs 10.7% NCT00565409
- 34% vs 10.7% NCT00565409
- 33% vs 10.2% NCT00565409
- 35.5% vs 11.2% NCT00565409
- 31% vs 10.2% NCT00565409
- 28% vs 9.6% NCT00565409
- 28.7% vs 17.6% NCT00565409
- 42% vs 33% NCT00565409
- 31.3% vs 10.7% NCT00565409
- 30.3% vs 10.7% NCT00565409
- 28.9% vs 10.2% NCT00565409
- 31.3% vs 11.2% NCT00565409
- 31.3% vs 10.2% NCT00565409
- 30.8% vs 9.6% NCT00565409
- 27.9% vs 17.6% NCT00565409
- 33.3% vs 33% NCT00565409
- 74.6% vs 38.5% NCT00913458
- 77.8% vs 36.9% NCT00913458
- 69.8% vs 38.5% NCT00913458
- 73% vs 56.9% NCT00913458
- 82.5% vs 80% NCT00913458
- 16% vs 12.5% NCT01313208
- 17% vs 10.6% NCT01313208
- 8.5% vs 9.6% NCT01313208
- 5.7% vs 1% NCT01313208
- 5.7% vs 0% NCT01313208
- 1.9% vs 0% NCT01313208
- 1.9% vs 0% NCT01313208
- 41.9% vs 34.1% NCT00848354
- 39.6% vs 34.1% NCT00848354
- 53.1% vs 38.3% NCT00848354
- 45% vs 32.5% NCT00848354
- 49.0% vs 36.7% NCT00848354
- 40.4% vs 30.2% NCT00848354
- 48.5% vs 35% NCT00848354
- 34.8% vs 11.3% NCT00848354
- 49.0% vs 40% NCT00848354
- 30.1% vs 10.6% NCT00848354
- 27.6% vs 9.2% NCT00848354
- 20.1% vs 4.2% NCT00848354
- 16.1% vs 3.5% NCT00848354
- 7.2% vs 2.1% NCT00848354
- 3.6% vs 0.7% NCT00848354
DAS28-CRP remission
- adalimumab
- 38.5% vs 42.9%vs Standard of CareNCT01162421
5 other results
- 30.8% vs 34.3% NCT01162421
- 35.9% vs 22.9% NCT01162421
- 28.2% vs 31.4% NCT01162421
- 35.9% vs 11.4% NCT01162421
- 17.9% vs 8.6% NCT01162421
- etanercept
- 54.5% vs 69.1%vs Standard COBRA-Slim InductionNCT03649061
1 other result
- 58.2% vs 43.6% NCT03649061
HAQ-DI, change
- adalimumab
- -0.6 vs -0.3−0.3 vs placeboNCT00195702
22 other results
- -0.6 vs -0.3 NCT00195702
- -0.6 vs -0.2 NCT00195702
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.3 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.5 vs -0.3 NCT00538902
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.4 vs -0.3 NCT00538902
- -0.6 vs -0.2 NCT00195702
- -0.8 vs -0.8 NCT00195663
- -1.1 vs -0.8 NCT00195663
- -0.6 vs -0.7 NCT01500278
- -0.5 vs -0.6 NCT01162421
- -0.6 vs -0.6 NCT01162421
- -0.5 vs -0.6 NCT01162421
- -0.5 vs -0.5 NCT01162421
- -0.5 vs -0.3 NCT01162421
- -0.4 vs -0.4 NCT01162421
- etanercept
- -0.6 vs -0.3vs MethotrexateNCT00445770
31 other results
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.2 NCT00445770
- -0.4 vs -0.1 NCT00445770
- -0.3 vs -0.1 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.2 NCT00445770
- -0.3 vs -0.1 NCT00445770
- -0.3 vs -0.1 NCT00445770
- -0.5 vs -0.4 NCT01313208
- -0.4 vs -0.4 NCT01313208
- -0.4 vs -0.3 NCT01313208
- -0.4 vs -0.2 NCT01313208
- -0.4 vs -0.2 NCT01313208
- -0.3 vs -0.2 NCT01313208
- -0.3 vs -0.1 NCT01313208
- -0.8 vs -0.5 NCT00848354
- 0.9 vs 0.7 NCT03649061
- 0.8 vs 0.7 NCT03649061
Modified Sharp score, change
- adalimumab
- 0.1 vs 2.7−2.6 vs placeboNCT00195702
15 other results
- 0.8 vs 2.7 NCT00195702
- 1.5 vs 2.4 NCT00870467
- 3 vs 5.7 NCT00195663
- 1.3 vs 5.7 NCT00195663
- 0.3 vs 1.3 NCT00195702
- 0.1 vs 4.8 NCT00195702
- 0.7 vs 6.2 NCT00195702
- 0.6 vs 1.3 NCT00195702
- 1.2 vs 4.8 NCT00195702
- 2.6 vs 6.2 NCT00195702
- 5.5 vs 10.4 NCT00195663
- 1.9 vs 10.4 NCT00195663
- 0.0 vs 2.2 NCT01162421
- 0.2 vs 1.6 NCT01162421
- 0.0 vs 0.9 NCT01162421
- etanercept
- 3.3 vs 9.8vs MethotrexateNCT00445770
11 other results
- 5.2 vs 9.8 NCT00445770
- 1.7 vs 5.1 NCT00445770
- 2.4 vs 5.1 NCT00445770
- 0 vs 0.5 NCT00913458
- 0 vs -1 NCT00858780
- 0 vs -1 NCT00858780
- 7 vs 7.3 NCT00259610
- 4.8 vs 7.3 NCT00259610
- 0.4 vs 1.4 NCT00848354
- 0.8 vs 0.7 NCT03649061
- 0.3 vs 0.5 NCT03649061
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
37 other shared endpoints and safety
Coverage. adalimumab: 41 of 41 rows · etanercept: 41 of 41 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | etanercept Rows use multiple source trials |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 97% (n=133) @ 52wk*a,b,c,d NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 129 participants as posted show 1 more dose80% (n=5) @ 52wk* NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 4 participants as posted | 69.3% (n=306) @ 52wk*50 mg QWb,c,d NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 212 Participants as posted |
| ACR50 responder rate · % of participants No placebo or comparator arm | 88% (n=133) @ 52wk*a,b,c,d NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 117 participants as posted show 1 more dose40% (n=5) @ 52wk* NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 2 participants as posted | 66% (n=306) @ 52wk*50 mg QWb,c,d NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 202 Participants as posted |
| ACR70 responder rate · % of participants No placebo or comparator arm | 65.4% (n=133) @ 52wk*a,b,c,d NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted show 1 more dose0% (n=5) @ 52wk* NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 0 participants as posted | 57.5% (n=306) @ 52wk*50 mg QWb,c,d NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 176 Participants as posted |
| ACR90 responder rate · % of participants No placebo or comparator arm | 16.3% (n=98) @ 26wk20 mg MTXa,b,c NCT01185301 · Phase 3 · registry result, not featured evidence · combination show 3 more doses17.2% (n=99) @ 26wk10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 10% (n=100) @ 26wk5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 7.1% (n=98) @ 26wk2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination | 22.9% (n=306) @ 26wk*50 mg QWb,c NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 70 Participants as posted |
| CDAI absolute change · score | -26.3 vs -27.99 ABBV-3373 score @ 12wke,c NCT03823391 · Phase 2 · registry result, not featured evidence | 3.15 vs 5.39 Methotrexate score @ 12wka,e,c NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy show 1 more dose3.24 vs 5.39 Methotrexate score @ 12wk NCT02373813 · Phase 3 · registry result, not featured evidence · combination |
| CDAI Clinical Remission responder rate · % of participants | 55.2% (n=105) vs 48.2% (n=112) placebo @ 78wk*a,c,d,f NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted show 1 more dose15.1% (n=259) vs 48.2% (n=112) placebo @ 78wk* NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted | 8.5% (n=106) vs 3.8% (n=104) placebo @ 24wkc,d,f NCT01313208 · Phase 4 · registry result, not featured evidence |
| Clinical Remission responder rate · % of participants | 43.3% (n=30) vs 50% (n=8) placebo @ 16wk*c,d,g NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted | 21.4% (n=42) vs 7% (n=43) Methotrexate*c,d,g NCT00443430 · Phase 4 · registry result, not featured evidence · combination · converted to % from 9 participants as posted |
| CRP Change absolute change · mg | -11.2 vs -13.5 Standard of Care mg @ 104wkc,d,h NCT01162421 · Phase 4 · registry result, not featured evidence | 0 vs -1.42 placebo mg @ 48wk50 mga,c,d,h NCT00858780 · Phase 4 · registry result, not featured evidence show 1 more dose0 vs -1.42 placebo mg @ 48wk25 mg NCT00858780 · Phase 4 · registry result, not featured evidence |
| DAS Remission responder rate · % of participants No placebo or comparator arm | 57.2% (n=236) @ 520wk*b,c,d,i NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 135 participants as posted | 63.1% (n=306) @ 52wk*50 mg QWb,c,d,i NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 193 Participants as posted |
| DAS28 absolute change · score | -3.71 vs -3.04 placebo score @ 78wka,c,j NCT00420927 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-2.7 vs -3.04 placebo score @ 78wk NCT00420927 · Phase 4 · registry result, not featured evidence · combination | -3.41 vs -3.51 DMARD + Methotrexate score @ 128wkc,j NCT00848354 · Phase 4 · registry result, not featured evidence · combination |
| DAS28 absolute value · score | 3.54 vs 3.46 Adalimumab score @ 24wk40 mg every other weekk,c,d,l NCT01712178 · Phase 2 · registry result, not featured evidence | 1.99 vs 2.07 placebo score @ 36wk50 mga,k,c,d,l NCT00565409 · Phase 4 · registry result, not featured evidence · combination show 1 more dose2.06 vs 2.07 placebo score @ 36wk25 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination |
| DAS28 absolute change · score No placebo or comparator arm | -2.2 score @ 36wka,k,c,d NCT01752855 · Phase 2 · registry result, not featured evidence show 1 more dose-2.4 score @ 36wk NCT01752855 · Phase 2 · registry result, not featured evidence | -1.89 score @ 36wk50 mgk,c,d NCT00565409 · Phase 4 · registry result, not featured evidence · combination |
| DAS28 Low Disease Activity responder rate · % of participants | 58.8% (n=17) vs 54.8% (n=31) ABBV-3373 @ 12wkk,c,d NCT03823391 · Phase 2 · registry result, not featured evidence | 33% (n=106) vs 21.2% (n=104) placebo @ 12wkk,c,d NCT01313208 · Phase 4 · registry result, not featured evidence |
| DAS28 Remission responder rate · % of participants | 23.4% (n=274) vs 20.6% (n=257) Methotrexate @ 52wk*a,b,c NCT00195663 · Phase 3 · registry result, not featured evidence · converted to % from 64 participants as posted show 1 more dose42.9% (n=268) vs 20.6% (n=257) Methotrexate @ 52wk* NCT00195663 · Phase 3 · registry result, not featured evidence · combination · converted to % from 115 participants as posted | 49.8% (n=265) vs 27.8% (n=263) M @ 52wk*b,c NCT00195494 · Phase 4 · registry result, not featured evidence · combination · converted to % from 132 participants as posted |
| DAS28-CRP absolute change · score | -2.51 vs -2.65 ABBV-3373 score @ 12wke,c NCT03823391 · Phase 2 · registry result, not featured evidence | 0.42 vs 0.84 Methotrexate score @ 12wka,e,c NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy show 1 more dose0.41 vs 0.84 Methotrexate score @ 12wk NCT02373813 · Phase 3 · registry result, not featured evidence · combination |
| DAS28-ESR absolute change · score | -2.55 vs -2.76 ABBV-3373 score @ 12wkk,c,d,g NCT03823391 · Phase 2 · registry result, not featured evidence | 3 vs 2.9 MTX + SSZ + HCQ scorea,k,c,d,g NCT00259610 · Phase 4 · registry result, not featured evidence · combination show 1 more dose3.1 vs 2.9 MTX + SSZ + HCQ score NCT00259610 · Phase 4 · registry result, not featured evidence · combination |
| DAS28-ESR absolute change · score No placebo or comparator arm | -3.7 score @ 52wka,c,d,m NCT00870467 · Phase 3 · registry result, not featured evidence show 1 more dose-1.9 score @ 52wk NCT00870467 · Phase 3 · registry result, not featured evidence | -2.8 score @ 24wkc,d,m NCT02378506 · Phase 3 · registry result, not featured evidence |
| DAS28-ESR LDAS responder rate · % of participants | 35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wka,c,d,n NCT01500278 · Phase 4 · registry result, not featured evidence · combination show 2 more doses45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk NCT01500278 · Phase 4 · registry result, not featured evidence · combination 47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk NCT01500278 · Phase 4 · registry result, not featured evidence · combination | 43.6% (n=163) vs 17.3% (n=168) placebo @ 52wkc,d,n NCT01578850 · Phase 4 · registry result, not featured evidence |
| DAS28-ESR Remission responder rate · % of participants | 30.4% (n=171) vs 14.7% (n=163) placebo @ 26wk*b,c,d,o NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 52 participants as posted | 53.2% (n=163) vs 29.5% (n=168) placebo @ 52wkb,c,d,o NCT01578850 · Phase 4 · registry result, not featured evidence |
| Disease Flare responder rate · % of participants | 36.3% (n=102) vs 45% (n=20) placebop,c,d,g NCT02198651 · Phase 4 · registry result, not featured evidence 1 other source trial15.4% (n=39) vs 8.6% (n=35) Standard of Care @ 104wk NCT01162421 · Phase 4 · registry result, not featured evidence | 28% (n=25) vs 81% (n=26) placebo0.4 mg/kgp,c,d,g NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 1 other source trial52.1% (n=163) vs 79.8% (n=168) placebo @ 52wk NCT01578850 · Phase 4 · registry result, not featured evidence |
| Erosion absolute change · score | 1.7 vs 3.7 Methotrexate score @ 52wka,c NCT00195663 · Phase 3 · registry result, not featured evidence show 1 more dose0.8 vs 3.7 Methotrexate score @ 52wk NCT00195663 · Phase 3 · registry result, not featured evidence · combination | 2.03 vs 5.43 Methotrexate score @ 52wk25 mga,c NCT00445770 · Phase 3 · registry result, not featured evidence show 1 more dose2.75 vs 5.43 Methotrexate score @ 52wk10 mg NCT00445770 · Phase 3 · registry result, not featured evidence |
| EULAR Good responder rate · % of participants | 43.6% (n=39) vs 54.3% (n=35) Standard of Care @ 104wkc,d,q NCT01162421 · Phase 4 · registry result, not featured evidence | 75.73% (n=260) vs 70% (n=126) DMARD + Methotrexate @ 128wka,c,d,q NCT00848354 · Phase 4 · registry result, not featured evidence · combination show 1 more dose57.68% (n=260) vs 55% (n=126) DMARD + Methotrexate @ 128wk NCT00848354 · Phase 4 · registry result, not featured evidence · combination |
| EULAR Good, Moderate responder rate · % of participants | 63% (n=64) vs 63% (n=64) AbbVie Adalimumab @ 24wkb,c,d NCT03172325 · Phase 3 · registry result, not featured evidence | 92.45% (n=279) vs 65.49% (n=142) DMARD + Methotrexate @ 24wka,b,c,d NCT00848354 · Phase 4 · registry result, not featured evidence · combination show 1 more dose91.76% (n=279) vs 64.79% (n=142) DMARD + Methotrexate @ 24wk NCT00848354 · Phase 4 · registry result, not featured evidence · combination |
| HAQ-DI absolute change · score No placebo or comparator arm | -0.6 score @ 24wk40 mg or 80 mg every other weekc,d NCT00603993 · Phase 3 · registry result, not featured evidence 2 other source trials-0.4 score @ 24wk40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence -0.49 score @ 24wk40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | -0.5 score @ 24wkc,d NCT02378506 · Phase 3 · registry result, not featured evidence |
| Modified Sharp absolute change · score No placebo or comparator arm | 1.6 score @ 52wka,b,c NCT00870467 · Phase 3 · registry result, not featured evidence show 1 more dose9.6 score @ 52wk NCT00870467 · Phase 3 · registry result, not featured evidence | 0.1 score @ 52wka,b,c NCT00654368 · Phase 4 · registry result, not featured evidence · combination show 1 more dose0.3 score @ 52wk NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy |
| Morning Stiffness Duration absolute change · minutes No placebo or comparator arm | -104.8 minutes @ 36wk40 mg or 80 mg every other weekb,c,d NCT00603993 · Phase 3 · registry result, not featured evidence 1 other source trial-79.9 minutes @ 36wk40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence | -112.36 minutes @ 36wk50 mgb,c,d NCT00565409 · Phase 4 · registry result, not featured evidence · combination |
| mTSS no Progression event count · % of participants | 82.4% (n=102) vs 68.8% (n=112) placebo @ 78wk*a,c,r NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 84 Participants as posted show 1 more dose70.3% (n=259) vs 68.8% (n=112) placebo @ 78wk* NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 182 Participants as posted | 79.7% (n=246) vs 58.7% (n=230) M @ 52wk*c,r NCT00195494 · Phase 4 · registry result, not featured evidence · combination · converted to % from 196 participants as posted |
| Patient Global Assessment absolute change · score | -22.3 vs -22.4 Standard of Care score @ 52wkc,d NCT01162421 · Phase 4 · registry result, not featured evidence | -3.91 vs -3.02 placebo score @ 52wkc,d NCT01578850 · Phase 4 · registry result, not featured evidence 2 other source trials-3.04 vs -1.97 Methotrexate score @ 52wk10 mg NCT00445770 · Phase 3 · registry result, not featured evidence -2.91 vs -1.97 Methotrexate score @ 52wk25 mg NCT00445770 · Phase 3 · registry result, not featured evidence |
| Patient Global Assessment absolute change · score No placebo or comparator arm | -31.6 score @ 36wk40 mg or 80 mg every other weekb,c,d NCT00603993 · Phase 3 · registry result, not featured evidence 2 other source trials-26.9 score @ 36wk40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence -33 score @ 36wk40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | -2.46 score @ 36wk50 mgb,c,d NCT00565409 · Phase 4 · registry result, not featured evidence · combination |
| Physician Global Assessment absolute change · score | -47.3 vs -43.8 Standard of Care score @ 52wkc,d NCT01162421 · Phase 4 · registry result, not featured evidence | -4.77 vs -3.74 placebo score @ 52wkc,d NCT01578850 · Phase 4 · registry result, not featured evidence 2 other source trials-3.68 vs -2.72 Methotrexate score @ 52wk10 mg NCT00445770 · Phase 3 · registry result, not featured evidence -4.07 vs -2.72 Methotrexate score @ 52wk25 mg NCT00445770 · Phase 3 · registry result, not featured evidence |
| Physician Global Assessment absolute change · score No placebo or comparator arm | -42.2 score @ 36wk40 mg or 80 mg every other weekb,c,d NCT00603993 · Phase 3 · registry result, not featured evidence 2 other source trials-37.3 score @ 36wk40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence -34.3 score @ 36wk40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | -2.57 score @ 36wk50 mgb,c,d NCT00565409 · Phase 4 · registry result, not featured evidence · combination |
| RAMRIS Synovitis absolute change · score | -3.38 vs -3.88 placebo score @ 78wka,c,d,s NCT00420927 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-3.25 vs -3.88 placebo score @ 78wk NCT00420927 · Phase 4 · registry result, not featured evidence · combination | -0.16 vs -0.29 placebo score @ 12wk50 mga,c,d,s NCT00858780 · Phase 4 · registry result, not featured evidence show 1 more dose1.36 vs -0.29 placebo score @ 12wk25 mg NCT00858780 · Phase 4 · registry result, not featured evidence |
| SDAI absolute change · score | -27.42 vs -28.5 ABBV-3373 score @ 12wke,c NCT03823391 · Phase 2 · registry result, not featured evidence | 3.14 vs 5.67 Methotrexate score @ 12wka,e,c NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy show 1 more dose3.21 vs 5.67 Methotrexate score @ 12wk NCT02373813 · Phase 3 · registry result, not featured evidence · combination |
| SDAI Remission responder rate · % of participants | 52.4% (n=105) vs 45.5% (n=112) placebo @ 78wk*a,t,c,u NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 55 Participants as posted show 1 more dose15.1% (n=259) vs 45.5% (n=112) placebo @ 78wk* NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted | 49.5% (n=101) vs 28.7% (n=101) Methotrexate @ 48wka,t,c,u NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy show 5 more doses52.1% (n=101) vs 30.5% (n=101) Methotrexate @ 48wk NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy 55.9% (n=34) vs 54.2% (n=48) Methotrexate @ 48wk NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy 52.9% (n=51) vs 28.7% (n=101) Methotrexate @ 48wk NCT02373813 · Phase 3 · registry result, not featured evidence · combination 56.3% (n=51) vs 30.5% (n=101) Methotrexate @ 48wk NCT02373813 · Phase 3 · registry result, not featured evidence · combination 66.7% (n=15) vs 54.2% (n=48) Methotrexate @ 48wk NCT02373813 · Phase 3 · registry result, not featured evidence · combination |
| SF-36 MCS absolute change · score | 7.1 vs 6.5 Methotrexate score @ 52wka,b,c,v NCT00195663 · Phase 3 · registry result, not featured evidence show 1 more dose7.2 vs 6.5 Methotrexate score @ 52wk NCT00195663 · Phase 3 · registry result, not featured evidence · combination | 7.32 vs 6.42 DMARD + Methotrexate score @ 128wkb,c,v NCT00848354 · Phase 4 · registry result, not featured evidence · combination |
| SF-36 PCS absolute change · score | 12.6 vs 12.5 Methotrexate score @ 52wka,b,c,v NCT00195663 · Phase 3 · registry result, not featured evidence show 1 more dose16.7 vs 12.5 Methotrexate score @ 52wk NCT00195663 · Phase 3 · registry result, not featured evidence · combination | 13.47 vs 12.1 DMARD + Methotrexate score @ 128wkb,c,v NCT00848354 · Phase 4 · registry result, not featured evidence · combination |
| Swollen Joint Count absolute change · swollen joints | -10.6 vs -10.1 Standard of Care swollen joints @ 104wkc,d,h NCT01162421 · Phase 4 · registry result, not featured evidence | 0 vs 0.5 placebo swollen joints @ 48wk50 mga,c,d,h NCT00858780 · Phase 4 · registry result, not featured evidence show 1 more dose0 vs 0.5 placebo swollen joints @ 48wk25 mg NCT00858780 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 23.2%40 mg every other weekw NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 20.8%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 24.8%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 66.7% NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 32.5% NCT01162421 · Phase 4 · registry result, not featured evidence 10.3%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 12.3%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 9.2%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 6.1%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 7%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 15.3%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 39.4%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 26.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 36% NCT00690573 · Phase 3 · registry result, not featured evidence 9.4%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 62.1% NCT00195650 · Phase 3 · registry result, not featured evidence 5%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 8.2%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 11.2%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 47.6%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 4.1%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 2%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 9.1%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 64%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | —0.4 mg/kgx NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 show 44 more results62.5%Adult Participants NCT00357903 · Phase 3 · monotherapy 74.1%Pediatric Participants NCT00357903 · Phase 3 · monotherapy —Pediatric Subjects NCT00357903 · Phase 3 · monotherapy —Total Adults NCT00357903 · Phase 3 · monotherapy 16.4% NCT03649061 · Phase 4 · registry result, not featured evidence · combination — NCT01578850 · Phase 4 · registry result, not featured evidence 4.7%Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Etanercept-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Placebo-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence 4.3%Etanercept + Methotrexate NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 1 NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 29.9%Etanercept + Methotrexate NCT00654368 · Phase 4 · registry result, not featured evidence · combination 49%Etanercept Alone NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy 36.6%50 mg QW NCT00913458 · Phase 4 · registry result, not featured evidence · combination —E25 + MTX (Phase 2) NCT00913458 · Phase 4 · registry result, not featured evidence · combination —E25+MTX (Phase 3) NCT00913458 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT00858780 · Phase 4 · registry result, not featured evidence —25 mg NCT00858780 · Phase 4 · registry result, not featured evidence 9.4%50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination —25 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 9.5% NCT00443430 · Phase 4 · registry result, not featured evidence · combination 40.5%ETN Alone NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy 16.9%ETN+MTX NCT00688103 · Phase 4 · registry result, not featured evidence · combination 31.1% NCT00259610 · Phase 4 · registry result, not featured evidence · combination 2% NCT00422227 · Phase 4 · registry result, not featured evidence 19.3%Year 1 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy —Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · combination —Open Label Rescue: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination 31.3%Open Label Run-In: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination — NCT02986139 · Phase 3 · registry result, not featured evidence 13.3% NCT02378506 · Phase 3 · registry result, not featured evidence 17%25 mg NCT00445770 · Phase 3 · registry result, not featured evidence 18.2%10 mg NCT00445770 · Phase 3 · registry result, not featured evidence 8%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence 6.7%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence 2.4%50 mg once weekly NCT00418717 · Phase 3 · registry result, not featured evidence 14.3% NCT00361634 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weekw NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 —20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 1.3%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence — NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 12.5% NCT01162421 · Phase 4 · registry result, not featured evidence 3.9%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 4.5%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 3.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 0%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 9.9%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 11.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination — NCT00690573 · Phase 3 · registry result, not featured evidence —DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 22.9% NCT00195650 · Phase 3 · registry result, not featured evidence 3%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 4.4%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 11%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 0%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | —0.4 mg/kgx NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 show 44 more results15%Adult Participants NCT00357903 · Phase 3 · monotherapy 6.9%Pediatric Participants NCT00357903 · Phase 3 · monotherapy —Pediatric Subjects NCT00357903 · Phase 3 · monotherapy —Total Adults NCT00357903 · Phase 3 · monotherapy — NCT03649061 · Phase 4 · registry result, not featured evidence · combination — NCT01578850 · Phase 4 · registry result, not featured evidence 1.9%Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Etanercept-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Placebo-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence 1.8%Etanercept + Methotrexate NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 1 NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 5.6%Etanercept + Methotrexate NCT00654368 · Phase 4 · registry result, not featured evidence · combination 9.2%Etanercept Alone NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy 6.5%50 mg QW NCT00913458 · Phase 4 · registry result, not featured evidence · combination —E25 + MTX (Phase 2) NCT00913458 · Phase 4 · registry result, not featured evidence · combination —E25+MTX (Phase 3) NCT00913458 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT00858780 · Phase 4 · registry result, not featured evidence —25 mg NCT00858780 · Phase 4 · registry result, not featured evidence 2%50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination —25 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 2.4% NCT00443430 · Phase 4 · registry result, not featured evidence · combination 5.4%ETN Alone NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy 1.3%ETN+MTX NCT00688103 · Phase 4 · registry result, not featured evidence · combination 4.5% NCT00259610 · Phase 4 · registry result, not featured evidence · combination 1.5% NCT00422227 · Phase 4 · registry result, not featured evidence 9.9%Year 1 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy —Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · combination —Open Label Rescue: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination 0.8%Open Label Run-In: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination — NCT02986139 · Phase 3 · registry result, not featured evidence 7.4% NCT02378506 · Phase 3 · registry result, not featured evidence 10.4%25 mg NCT00445770 · Phase 3 · registry result, not featured evidence 7.8%10 mg NCT00445770 · Phase 3 · registry result, not featured evidence 5.8%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence 4.1%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence —50 mg once weekly NCT00418717 · Phase 3 · registry result, not featured evidence — NCT00361634 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 13%40 mg every other weekw NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 16%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 7.4%maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 4.5%reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 2.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 7.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 1%Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 0% NCT02451748 · Phase 4 · registry result, not featured evidence · combination 13% NCT01500278 · Phase 4 · registry result, not featured evidence · combination 10.3% NCT01162421 · Phase 4 · registry result, not featured evidence 7.1%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 3.9%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 11.4%ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 6.9%ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 7.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 23.7%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 20.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 24% NCT00690573 · Phase 3 · registry result, not featured evidence 4.1%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 51.1% NCT00195650 · Phase 3 · registry result, not featured evidence 1%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 4.9%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.3%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 6.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 1.9%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 35.9%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence —40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 12.5%Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 2.3%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 4.5%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 0%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence 0%Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 0%New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 40%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | 4%0.4 mg/kgx NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 show 44 more results—Adult Participants NCT00357903 · Phase 3 · monotherapy —Pediatric Participants NCT00357903 · Phase 3 · monotherapy 27.6%Pediatric Subjects NCT00357903 · Phase 3 · monotherapy 50.4%Total Adults NCT00357903 · Phase 3 · monotherapy 9.1% NCT03649061 · Phase 4 · registry result, not featured evidence · combination 0% NCT01578850 · Phase 4 · registry result, not featured evidence —Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence 3.8%Etanercept-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence 2.9%Placebo-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Etanercept + Methotrexate NCT00848354 · Phase 4 · registry result, not featured evidence · combination 3.6%Etanercept + Methotrexate Phase 1 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 6.5%Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 4.6%Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 15.9%Etanercept + Methotrexate NCT00654368 · Phase 4 · registry result, not featured evidence · combination 11.2%Etanercept Alone NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy 9.2%50 mg QW NCT00913458 · Phase 4 · registry result, not featured evidence · combination 4.8%E25 + MTX (Phase 2) NCT00913458 · Phase 4 · registry result, not featured evidence · combination 0%E25+MTX (Phase 3) NCT00913458 · Phase 4 · registry result, not featured evidence · combination 4.3%50 mg NCT00858780 · Phase 4 · registry result, not featured evidence 3.7%25 mg NCT00858780 · Phase 4 · registry result, not featured evidence 4.6%50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 6.4%50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 3.5%25 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 4.8% NCT00443430 · Phase 4 · registry result, not featured evidence · combination 2.8%ETN Alone NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy 11.8%ETN+MTX NCT00688103 · Phase 4 · registry result, not featured evidence · combination 14.3% NCT00259610 · Phase 4 · registry result, not featured evidence · combination 3% NCT00422227 · Phase 4 · registry result, not featured evidence —Year 1 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination 3%Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy 3.8%Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · combination 3.9%Open Label Rescue: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination 3.8%Open Label Run-In: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination 0.9% NCT02986139 · Phase 3 · registry result, not featured evidence 4.8% NCT02378506 · Phase 3 · registry result, not featured evidence 6%25 mg NCT00445770 · Phase 3 · registry result, not featured evidence 4.2%10 mg NCT00445770 · Phase 3 · registry result, not featured evidence 5.5%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence 2.9%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence —50 mg once weekly NCT00418717 · Phase 3 · registry result, not featured evidence 0% NCT00361634 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weekw injection site pain 17.9% (placebo 21.5%) upper respiratory tract infection 16.9% (placebo 11%) headache 11.6% (placebo 5%) NCT00195702 · Phase 3 show 40 more results20 mg weekly injection site pain 17.5% (placebo 21.5%) upper respiratory tract infection 16.5% (placebo 11%) headache 13.2% (placebo 5%) NCT00195702 · Phase 3 maximum tolerated dose liver function test abnormal 8.8% abdominal pain upper 2.9% dry mouth 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination reduced dose dry mouth 3% alanine aminotransferase increased 1.5% cough 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination 40 mg Eow cough 2.7% (placebo 5%) nasopharyngitis 2.7% (placebo 20%) urinary tract infection 1.4% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence 40 mg Eow nasopharyngitis 10.3% (placebo 20%) upper respiratory tract infection 7.7% (placebo 0%) hepatic enzyme increased 5.1% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.7% (placebo 20%) arthralgia 5.9% (placebo 0%) influenza 4.9% (placebo 10%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.3% headache 10.7% upper respiratory tract infection 10.3% NCT01500278 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 25.6% nasopharyngitis 20.5% alanine aminotransferase increased 15.4% NCT01162421 · Phase 4 · registry result, not featured evidence high dose nausea 10.3% upper respiratory tract infection 7.7% urinary tract infection 7.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination low dose nausea 9.7% fatigue 9.1% upper respiratory tract infection 9.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination cough 6.7% (placebo 3.6%) influenza 5.7% (placebo 2.7%) nasopharyngitis 5.7% (placebo 3.6%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 11.2% (placebo 6.3%) nasopharyngitis 8.9% (placebo 3.6%) alanine aminotransferase increased 6.2% (placebo 2.7%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination injection site reaction 8.8% headache 5.9% nausea 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 20 mg MTX nasopharyngitis 11.2% headache 9.2% alopecia 8.2% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 10 mg MTX nausea 13.1% alopecia 6.1% diarrhoea 6.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5 mg MTX diarrhoea 6% headache 6% nasopharyngitis 6% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2.5 mg MTX nausea 7.1% arthralgia 6.1% abdominal pain upper 4.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 22.6% headache 21.5% nausea 17.5% NCT00195663 · Phase 3 · registry result, not featured evidence nasopharyngitis 30.2% headache 20.5% upper respiratory tract infection 18.7% NCT00195663 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 56% upper respiratory tract infection 56% influenza 32% NCT00690573 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.2% (placebo 16.6%) hepatic function abnormal 8.2% (placebo 5.5%) alanine aminotransferase increased 7.6% (placebo 3.7%) NCT00870467 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 46.3% rheumatoid arthritis 25.4% sinusitis 24.9% NCT00195650 · Phase 3 · registry result, not featured evidence 40 mg/0.8 mL nasopharyngitis 4% respiratory disorder 4% headache 3% NCT01231321 · Phase 3 · registry result, not featured evidence 40 mg every other week nausea 5.5% (placebo 5.3%) headache 4.9% (placebo 5.3%) nasopharyngitis 4.9% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 6.6% (placebo 5.3%) upper respiratory tract infection 2.6% (placebo 7%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly upper respiratory tract infection 3.2% (placebo 7%) nasopharyngitis 2.7% (placebo 5.3%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly nausea 6.2% (placebo 5.3%) upper respiratory tract infection 5.2% (placebo 7%) headache 4.7% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg or 80 mg every other week nasopharyngitis 60.2% adverse drug reaction 29.5% antinuclear antibody positive 15.9% NCT00603993 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 45% adverse drug reaction 23.6% dna antibody positive 16.2% NCT00235872 · Phase 3 · registry result, not featured evidence 40 mg EOW upper respiratory tract infection 14% (placebo 11.7%) injection site pruritus 5.8% (placebo 0%) nasopharyngitis 5.8% (placebo 6.7%) NCT00538902 · Phase 2/3 · registry result, not featured evidence 80 mg EOW upper respiratory tract infection 12.4% (placebo 11.7%) nasopharyngitis 7.4% (placebo 6.7%) injection site pruritus 4.1% (placebo 0%) NCT00538902 · Phase 2/3 · registry result, not featured evidence urinary tract infection 11.8% abdominal discomfort 5.9% arthralgia 5.9% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 12.5% bronchitis 6.3% drug hypersensitivity 6.3% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 15.9% rheumatoid arthritis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence nasopharyngitis 13.6% cystitis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence 40 mg every other week nasopharyngitis 10% cystitis 8% nausea 8% NCT01712178 · Phase 2 · registry result, not featured evidence pharyngitis 1.6% rash erythematous 1.6% protein urine present 0% NCT01561313 · Phase 2 · registry result, not featured evidence protein urine present 1.6% pharyngitis 0% rash erythematous 0% NCT01561313 · Phase 2 · registry result, not featured evidence 40 mg Eow nasopharyngitis 60% diarrhoea 24% pruritus 20% NCT00235833 · Phase 2 · registry result, not featured evidence | 0.4 mg/kgx upper respiratory tract infection 40% (placebo 15.4%) headache 20% (placebo 11.5%) gastroenteritis 12% (placebo 3.8%) NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 show 40 more resultsupper respiratory tract infection 62.1% headache 34.5% pharyngitis 22.4% NCT00357903 · Phase 3 · monotherapy upper respiratory tract infection 35.6% sinusitis 20.8% bronchitis 15.3% NCT00357903 · Phase 3 · monotherapy nausea 25.5% fatigue 23.6% hepatic function abnormal 16.4% NCT03649061 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 2.4% (placebo 5.1%) NCT01578850 · Phase 4 · registry result, not featured evidence injection site erythema 12.3% rheumatoid arthritis 11.3% headache 8.5% NCT01313208 · Phase 4 · registry result, not featured evidence headache 15.4% upper respiratory tract infection 12.5% nasopharyngitis 11.5% NCT01313208 · Phase 4 · registry result, not featured evidence bronchitis 6.4% influenza 5.3% nasopharyngitis 5% NCT00848354 · Phase 4 · registry result, not featured evidence · combination bronchitis 4.2% influenza 4.2% nasopharyngitis 4.2% NCT00848354 · Phase 4 · registry result, not featured evidence · combination bronchitis 7.1% nasopharyngitis 4.6% urinary tract infection 4.6% NCT00848354 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 17.8% nasopharyngitis 11.2% sinusitis 10.3% NCT00654368 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 13.3% nasopharyngitis 10.2% headache 9.2% NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy 50 mg QW nasopharyngitis 12.7% (placebo 4.6%) nausea 12.7% (placebo 0%) headache 6.5% (placebo 0%) NCT00913458 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.9% (placebo 4.6%) upper respiratory tract infection 6.3% (placebo 4.6%) rheumatoid arthritis 3.2% (placebo 9.2%) NCT00913458 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 18.9% (placebo 9.2%) nasopharyngitis 5.7% (placebo 4.6%) alanine aminotransferase increased 0% (placebo 0%) NCT00913458 · Phase 4 · registry result, not featured evidence · combination 50 mg nasopharyngitis 26.1% (placebo 8.7%) upper respiratory tract infection 26.1% (placebo 8.7%) back pain 13% (placebo 0%) NCT00858780 · Phase 4 · registry result, not featured evidence 25 mg nasopharyngitis 29.6% (placebo 8.7%) arthralgia 11.1% (placebo 0%) gastroenteritis 11.1% (placebo 0%) NCT00858780 · Phase 4 · registry result, not featured evidence 50 mg headache 6.1% (placebo 0%) nasopharyngitis 5.8% (placebo 5%) bronchitis 0% (placebo 3%) NCT00565409 · Phase 4 · registry result, not featured evidence · combination 50 mg nasopharyngitis 8.9% (placebo 5%) bronchitis 5.9% (placebo 3%) pharyngitis 1.5% (placebo 5.5%) NCT00565409 · Phase 4 · registry result, not featured evidence · combination 25 mg bronchitis 5.4% (placebo 3%) nasopharyngitis 5% (placebo 5%) pharyngitis 2.5% (placebo 5.5%) NCT00565409 · Phase 4 · registry result, not featured evidence · combination liver function test elevation 7.1% NCT00443430 · Phase 4 · registry result, not featured evidence · combination upper airway viral infection 40.8% rash 26.8% injection site reaction 22.5% NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy upper airway viral infection 43.4% injection site reaction 11.8% gastroentelitis 10.5% NCT00688103 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 53.7% (placebo 57.3%) joint pain 27% (placebo 22.4%) dermatalogic eruption 14.8% (placebo 14.5%) NCT00259610 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 13.7% alanine aminotransferase increased 5.6% aspartate aminotransferase increased 3.6% NCT00422227 · Phase 4 · registry result, not featured evidence administration site conditions 24.5% nausea 19.3% investigations 17.9% NCT00195494 · Phase 4 · registry result, not featured evidence · combination infections and infestations 44.1% injury, poisoning and procedural complications 13.5% nasopharyngitis 9% NCT00195494 · Phase 4 · registry result, not featured evidence · combination infections and infestations 42.3% injury, poisoning and procedural complications 11.7% nasopharyngitis 9% NCT00195494 · Phase 4 · registry result, not featured evidence · combination infections and infestations 36.7% injury, poisoning and procedural complications 12.2% nasopharyngitis 11.1% NCT00195494 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 7.1% bronchitis 3% upper respiratory tract infection 3% NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy bronchitis 7.5% rheumatoid arthritis 5.7% upper respiratory tract infection 1.9% NCT02373813 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 6.8% rheumatoid arthritis 1.9% bronchitis 0% NCT02373813 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 5.4% bronchitis 1.6% rheumatoid arthritis 0.8% NCT02373813 · Phase 3 · registry result, not featured evidence · combination hypoaesthesia 1.9% pain in extremity 1.9% cellulitis 0.9% NCT02986139 · Phase 3 · registry result, not featured evidence injection site erythema 10.7% nasopharyngitis 7% upper respiratory tract infection 7% NCT02378506 · Phase 3 · registry result, not featured evidence 25 mg nasopharyngitis 20.3% upper respiratory tract infection 11.5% pharyngitis 8.2% NCT00445770 · Phase 3 · registry result, not featured evidence 10 mg nasopharyngitis 23.4% upper respiratory tract infection 10.4% pharyngitis 9.4% NCT00445770 · Phase 3 · registry result, not featured evidence 50 mg injection site reaction 14.2% injection site erythema 7.7% nasopharyngitis 6.8% NCT00459706 · Phase 3 · registry result, not featured evidence 50 mg injection site reaction 17.6% injection site erythema 9.3% nasopharyngitis 8.3% NCT00459706 · Phase 3 · registry result, not featured evidence 50 mg once weekly infections and infestations 28.6% dizziness 7.1% headache 4.8% NCT00418717 · Phase 3 · registry result, not featured evidence dry skin 23.1% injection site reaction 23.1% cough 15.4% NCT00361634 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eTrial phases differ: Phase 2 versus Phase 3.
- fAssessment timepoints differ: 78 weeks versus 24 weeks.
- gThe assessment timepoint is not available for both results.
- hAssessment timepoints differ: 104 weeks versus 48 weeks.
- iAssessment timepoints differ: 520 weeks versus 52 weeks.
- jAssessment timepoints differ: 78 weeks versus 128 weeks.
- kTrial phases differ: Phase 2 versus Phase 4.
- lAssessment timepoints differ: 24 weeks versus 36 weeks.
- mAssessment timepoints differ: 52 weeks versus 24 weeks.
- nAssessment timepoints differ: 104 weeks versus 52 weeks.
- oAssessment timepoints differ: 26 weeks versus 52 weeks.
- pTrial phases differ: Phase 4 versus Phase 2/3.
- qAssessment timepoints differ: 104 weeks versus 128 weeks.
- rAssessment timepoints differ: 78 weeks versus 52 weeks.
- sAssessment timepoints differ: 78 weeks versus 12 weeks.
- tTrial phases differ: Phase 4 versus Phase 3.
- uAssessment timepoints differ: 78 weeks versus 48 weeks.
- vAssessment timepoints differ: 52 weeks versus 128 weeks.
- wPopulation comparability has not been reviewed for these studies.
- xPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 1 more result
show 1 more result
show 7 more results
show 1 more result
show 1 more result
show 7 more results
show 2 more results
show 5 more results
show 5 more results
+ 193 further endpoints in the CSV export.
etanercept
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 195 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · etanercept's landscape